Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes: Protocol for a Kidney End Points Real-world Study (COMBi-KID Study)

BACKGROUND: Sodium-glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) are both considered to be part of standard care in the management of glycemia in type 2 diabetes. Recent trial evidence has indicated benefits on primary kidney end points for ind...

Descripción completa

Detalles Bibliográficos
Autores principales: Feher, Michael, Hinton, William, Forbes, Anna, Munro, Neil, Joy, Mark, Wheeler, David, de Lusignan, Simon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JMIR Publications 2022
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346560/
https://www.ncbi.nlm.nih.gov/pubmed/35852840
http://dx.doi.org/10.2196/34206

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346560/
https://www.ncbi.nlm.nih.gov/pubmed/35852840
http://dx.doi.org/10.2196/34206

Ejemplares similares